Who
Edward Carr
Chief Accounting Officer
Company insider
Files Form 4 as: Chief Accounting Officer, Dianthus Therapeutics; Chief Financial Officer, Abeona Therapeutics.
In numbers
- Trades disclosed
- 64
- Buys
- 0
- Sells
- 6
- Bought
- $0
- Sold
- $11.3M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 19 Nov 2018
- Last trade
- 17 Sep 2026
- Last filed
- 18 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Sep 2026filed 18 Sep 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Code M | $358K20,000 at $17.88 | filing |
| 17 Sep 2026filed 18 Sep 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Sold | $796K7,928 at $100.43 | filing |
| 17 Sep 2026filed 18 Sep 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Sold | $686K6,771 at $101.37 | filing |
| 17 Sep 2026filed 18 Sep 2026 | DNTH Dianthus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —20,000 at $0.00 | filing |
| 17 Sep 2026filed 18 Sep 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Sold | $358K3,501 at $102.39 | filing |
| 17 Sep 2026filed 18 Sep 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Sold | $114K1,100 at $103.20 | filing |
| 17 Sep 2026filed 18 Sep 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Sold | $73K700 at $104.39 | filing |
| 17 Sep 2026filed 18 Sep 2026 | DNTH Dianthus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —20,000 at $0.00 | filing |
| 17 Sep 2026filed 18 Sep 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Code M | $358K20,000 at $17.88 | filing |
| 17 Sep 2026filed 18 Sep 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Sold | $796K7,928 at $100.43 | filing |
| 17 Sep 2026filed 18 Sep 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Sold | $686K6,771 at $101.37 | filing |
| 17 Sep 2026filed 18 Sep 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Sold | $358K3,501 at $102.39 | filing |
| 17 Sep 2026filed 18 Sep 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Sold | $114K1,100 at $103.20 | filing |
| 17 Sep 2026filed 18 Sep 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Sold | $73K700 at $104.39 | filing |
| 12 Mar 2026filed 13 Mar 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Code M | $289K16,182 at $17.88 | filing |
| 12 Mar 2026filed 13 Mar 2026 | DNTH Dianthus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —17,500 at $0.00 | filing |
| 12 Mar 2026filed 13 Mar 2026 | DNTH Dianthus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 12 Mar 2026filed 13 Mar 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Code M | $386K17,500 at $22.07 | filing |
| 12 Mar 2026filed 13 Mar 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Code M | $218K10,000 at $21.77 | filing |
| 12 Mar 2026filed 13 Mar 2026 | DNTH Dianthus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —16,182 at $0.00 | filing |
News
Analyzing Connect Biopharma (NASDAQ:CNTB) & Dianthus Therapeutics (NASDAQ:DNTH)DNTH · tickerreport.com · 22 Oct 2026Dianthus Therapeutics Recognized Among Fortune's 2026 Best Workplaces In BioPharmaDNTH · manilatimes.net · 13 Oct 2026
0 headlines in the last 90 days name Edward Carr; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.